Roche Sues Pfizer to Block Biosimilar of Cancer Drug Herceptin

(Ref: Bloomberg)
  • Roche has filed a lawsuit seeking to block Pfizer from launching a biosimilar of Herceptin in the US, Bloomberg reported.

  • In the litigation filed in US federal court, Roche's Genentech unit argued that the proposed biosimilar, named PF-05280014, would violate 40 patents covering Herceptin.

  • Roche is additionally seeking compensation for lost revenue if Pfizer launches its biosimilar before patents for Herceptin expire.

  • "We will respond in court at the appropriate time," Pfizer spokesman Thomas Biegi remarked, adding "we’re committed to making this important treatment option available to physicians and patients."

  • The US Patent Trial and Appeal Board has agreed to review the validity of three patents covering the drug following challenges by Pfizer's Hospira unit, with decisions anticipated next year.

  • Meanwhile, Samsung Bioepis' Herceptin biosimilar Ontruzant was cleared in Europe earlier this month.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>